Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 11:51pm CET
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02/23 JOHNSON & JOHNSON : S&P upgrades Google's owner to its second-highest ranking
02/23 JOHNSON & JOHNSON : Anti-diarrhea medication ripe for abuse by opioid addicts, a..
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21 JOHNSON & JOHNSON : Ford Still Can Repair its Brand in South Africa but it Needs..
02/21 JOHNSON & JOHNSON : Ford still can repair its brand in South Africa but it needs..
02/20 MEDTRONIC : Global High Speed Surgical Drill Market- Medtronic, Johnson and John..
02/17 JOHNSON & JOHNSON : publishes prospectus for Actelion tender offer
02/17 Cosmetic Product Market 2017 - L Oreal, the Procter & Gamble, Unilever, Shise..
02/16 JOHNSON & JOHNSON : Global First Aid Kit Market- Hartmann, Honeywell, Johnson & ..
More news
Sector news : Pharmaceuticals - NEC
12:59a Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
02/23DJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
02/23DJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03:02a Is It Time To Sell Everything But High Quality Stocks?
02/23 Can 20 Financial Ratios Measure A Company's Moat Just Like Morningstar? Updat..
02/23 Why I Doubled Down On Johnson & Johnson
02/23 SEEKING ALPHA INTERVIEWS : Bret Jensen On Promising Drugs And Acquisition Target..
02/23 Back To The Future With Wright Medical
Advertisement
Financials ($)
Sales 2017 74 655 M
EBIT 2017 23 131 M
Net income 2017 18 272 M
Finance 2017 22 793 M
Yield 2017 2,75%
P/E ratio 2017 18,25
P/E ratio 2018 17,10
EV / Sales 2017 4,13x
EV / Sales 2018 3,90x
Capitalization 331 089 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 125 $
Spread / Average Target 3,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.74%331 089
ROCHE HOLDING LTD.5.98%209 906
PFIZER INC.3.42%206 688
NOVARTIS AG3.51%201 806
MERCK & CO., INC.10.91%181 558
SANOFI4.38%109 628
More Results